Hypoxia-Inducible Factor-Prolyl-Hydroxylase and Sodium-Glucose Cotransporter 2 Inhibitors for Low-Risk Myelodysplastic Syndrome-Related Anemia in Patients with Chronic Kidney Disease: A Report of Three Cases.
Hypoxia-Inducible Factor-Prolyl-Hydroxylase and Sodium-Glucose Cotransporter 2 Inhibitors for Low-Risk Myelodysplastic Syndrome-Related Anemia in Patients with Chronic Kidney Disease: A Report of Three Cases.
复制标题
DOI：
10.3390/hematolrep15010019
复制
发表时间：
2023-03-06
影响因子：
0.9
通讯作者：
Horiuchi, Takahiko
中科院分区：
文献类型：
--
作者：
Yamasaki, Satoshi;Horiuchi, Takahiko
关键词：
尽管达Produstat(一种低氧诱导因子Pro羟基酶抑制剂)和Dapagliflzin(一种钠-葡萄糖协同转运体2抑制剂)在日本已被批准用于治疗肾性贫血，但它们对80岁或80岁以上患有低风险骨髓增生综合征(MDS)相关性贫血的患者的有效性和安全性尚未得到证实。我们的病例系列包括两名男性和一名女性，年龄80岁，患有低风险的MDS相关贫血和糖尿病(DM)相关的慢性肾脏疾病，他们依赖红细胞输注，并且红细胞刺激药物不足。所有三名患者都接受了达Produstat和额外的达帕格列夫秦治疗，实现了红细胞输注的独立，并获得了6个 月的随访。达Produstat每日口服耐受性良好。在达Produstat开始治疗后6个月的随访中，没有死亡或进展为急性髓系白血病。在这些结果的基础上，我们认为24毫克达洛司特联合每天10毫克达帕利嗪是治疗低风险MDS相关贫血的有效形式。需要进一步的研究来阐明达Produstat和达帕利福秦的协同效应，这两种药物通过促进内源性促红细胞生成素的产生和正常化铁代谢来纠正慢性肾脏疾病相关贫血，从而长期管理低风险的MDS。
Although daprodustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor, and dapagliflozin, a sodium-glucose cotransporter 2 inhibitor, have been approved for the treatment of renal anemia in Japan, their efficacy and safety for patients aged 80 years or older with low-risk myelodysplastic syndrome (MDS)-related anemia have not been demonstrated. Our case series comprised two men and one woman aged >80 years with low-risk MDS-related anemia and diabetic mellitus (DM)-related chronic kidney disease who were dependent on red blood cell transfusions and in whom erythropoiesis-stimulating agents had been insufficient. All three patients received daprodustat and additional dapagliflozin achieved red blood cell transfusion independence and were followed up for >6 months. Daily oral daprodustat was well tolerated. There were no fatalities or progression to acute myeloid leukemia during the >6-month follow-up after daprodustat initiation. On the basis of these outcomes, we consider 24 mg of daprodustat combined with 10 mg of dapagliflozin daily an effective form of treatment for low-risk MDS-related anemia. Further studies are required to clarify the synergistic effects of daprodustat and dapagliflozin, which correct chronic kidney disease-related anemia by promoting endogenous erythropoietin production and normalizing iron metabolism to manage low-risk MDS in the long term.
登录
查看更多内容
影响因子：
11.4
作者：
通讯作者：
--
DOI：
10.1084/jem.20201544
发表时间：
2021-07-05
期刊：
The Journal of experimental medicine
影响因子：
--
作者：
Trowbridge JJ;Starczynowski DT
通讯作者：
Starczynowski DT
影响因子：
12.8
作者：
Steensma DP
通讯作者：
Steensma DP
影响因子：
3.2
作者：
Kurata, Yu;Nangaku, Masaomi
通讯作者：
Nangaku, Masaomi
DOI：
10.1124/jpet.117.242503
发表时间：
2017-12-01
影响因子：
3.5
作者：
Ariazi, Jennifer L.;Duffy, Kevin J.;Erickson-Miller, Connie
通讯作者：
Erickson-Miller, Connie